Mitsubishi UFJ Asset Management Co. Ltd. Buys 68,122 Shares of Stryker Corporation $SYK

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Stryker Corporation (NYSE:SYK) by 8.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 847,430 shares of the medical technology company’s stock after purchasing an additional 68,122 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Stryker were worth $266,805,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sankala Group LLC bought a new position in Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the third quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter worth about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter valued at approximately $28,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Stryker Stock Down 2.2%

Shares of NYSE SYK opened at $331.75 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average of $325.21 and a 200-day moving average of $333.24. The firm has a market capitalization of $127.25 billion, a price-to-earnings ratio of 34.38, a PEG ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Barclays lowered their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target for the company. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, Piper Sandler decreased their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.